IN8bio

IN8bio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of IN8bio (INAB) as of Oct 17, 2026 is -19.86 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -30.44 M USD — a change of -34.75% (higher).

EBITDA

-19.86 MUSD

YoY

-34.75%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of IN8bio is 2025 -19.86 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of IN8bio was 2024 -30.44 M USD. It decreases by -34.75% higher compared to the previous year.

The IN8bio EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-2.07 M USD
Jan 1, 2019
-5.13 M USD
Jan 1, 2020
-8.56 M USD
Jan 1, 2021
-14.65 M USD
Jan 1, 2022
-28.52 M USD
Jan 1, 2023
-30.34 M USD
Jan 1, 2024
-30.44 M USD
Jan 1, 2025
-19.86 M USD
The IN8bio EBITDA history
YEAREBITDAYoY
-19.86 MUSD-34.75%
-30.44 MUSD+0.33%
-30.34 MUSD+6.37%
-28.52 MUSD+94.64%
-14.65 MUSD+71.24%
-8.56 MUSD+66.67%
-5.13 MUSD+148.38%
-2.07 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IN8bio Stock analysis

What does IN8bio do? IN8bio Inc is a clinical-stage biopharmaceutical company based in New York City, operating in the Health Care sector within the Biotechnology industry. The company develops novel therapies using allogeneic, autologous, and genetically modified gamma-delta T cells for treating cancers, including solid tumors and hematologic malignancies. With 26 employees, it focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates, currently advancing Phase 1 and Phase 2 clinical trials for glioblastoma and other cancer treatments. IN8bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IN8bio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of IN8bio is -19.86 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of IN8bio changed from -30.44 M USD to -19.86 M USD, representing a -34.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) IN8bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s IN8bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — IN8bio

All Key Metrics — IN8bio